Stock Market News

1 month Sarepta Therapeutics (NASDAQ:SRPT) Earns Buy Rating from Analysts at Jefferies Financial GroupMarketBeat

Jefferies Financial Group initiated coverage on Sarepta Therapeutics in a research note on Monday. They set a “buy” rating and a $165.00 price objective on the stock.

Jefferies Financial (JEF) · Nasdaq 100 · Science

3 hours JMP Securities Raises BlackLine, Inc. (BL) Price Target to $86, Highlights $45B Market OpportunityInsider Monkey X

4 hours Equinix, Inc. (EQIX) Price Target Raised to $975 by Argus on Strong Growth Prospects and Positive MomentumInsider Monkey X

4 hours Advanced Micro Devices, Inc. (AMD) Set to Expand AI Portfolio with Affordable Krackan Point Processor LeakInsider Monkey X

4 hours Meta Platforms, Inc. (META) Advances Plans for $10 Billion AI Data Center in LouisianaInsider Monkey X

6 hours Amazon.com, Inc. (AMZN) Faces Potential EU Antitrust Investigation Over Marketplace Practices, Could Face Hefty FinesInsider Monkey X

6 hours Microsoft Corporation (MSFT) Unveils New AI Products and Features at Ignite, CEO Satya Nadella Highlights Rapid AI Investment GrowthInsider Monkey X

6 hours Alphabet Inc. (GOOG) Partners with Rezolve AI to Enhance Conversational Commerce SolutionsInsider Monkey X

6 hours Cadence (CDNS) Unveils First Arm-Based Chiplet: Boosting AI Efficiency and PowerInsider Monkey X

6 hours Fortinet, Inc (FTNT) and Skylark Launch AI-Powered Cybersecurity Centre in ChennaiInsider Monkey X

6 hours GlobalFoundries (GFS) Faces Market Oversupply: UBS Initiates Neutral RatingInsider Monkey X

6 hours QUALCOMM Incorporated (QCOM) CEO Cristiano Amon Dismisses Rumors of Intel Acquisition Amid AI Expansion into Cars and IoTInsider Monkey X

6 hours NVIDIA Corporation (NVDA) Beats Expectations with 70% YoY Revenue Growth and Strong AI Enterprise Demand, Citi Analyst SaysInsider Monkey X

7 hours FIFA, Mythical Games collaborate to launch blockchain game FIFA RivalsCointelegraph X

9 hours Lucid Is Shifting Into Higher Gear. Is the Stock a Buy Now?The Motley Fool X

9 hours 3 Dividend Stocks to Double Up on Right NowThe Motley Fool X

9 hours This Might Just Be Rivian’s Best Decision YetThe Motley Fool X

10 hours Is CrowdStrike Holdings a Buy?The Motley Fool X

10 hours Is Buying Airbnb Stock Below $135 a Smart Idea?The Motley Fool X

11 hours Can Anything Stop Nvidia?The Motley Fool X

11 hours Could Buying Apple Stock Today Set You Up for Life?The Motley Fool X

13 hours Should You Buy PayPal Stock While It’s Below $87?The Motley Fool X

13 hours Should You Buy PayPal Stock While It’s Below $87?The Motley Fool X

15 hours Got $1,500? Buy Iovance Biotherapeutics Now and Don’t Look BackThe Motley Fool X

15 hours Got $1,500? Buy Iovance Biotherapeutics Now and Don’t Look BackThe Motley Fool X

16 hours Supermicro Shares Soar as It Looks to Avoid Being Delisted. Is Now a Good Time to Buy the Beaten-Down Stock?The Motley Fool X

16 hours Supermicro Shares Soar as It Looks to Avoid Being Delisted. Is Now a Good Time to Buy the Beaten-Down Stock?The Motley Fool X

16 hours Advanced Micro Devices, Inc. (AMD) CEO Lisa Su Advocates for Open-Source AI Ecosystem and Holistic Data Center Design in IndiaInsider Monkey X

16 hours This 1 Investing Rule From Warren Buffett Could Supercharge (or Sink) Your PortfolioThe Motley Fool X

16 hours This 1 Investing Rule From Warren Buffett Could Supercharge (or Sink) Your PortfolioThe Motley Fool X

16 hours Regeneron Pharmaceuticals, Inc. (REGN): Among the Most Promising Cancer Stocks According to Hedge FundsInsider Monkey X

16 hours Merus NV (MRUS): Among the Most Promising Cancer Stocks According to Hedge FundsInsider Monkey X

16 hours Nvidia Stock Investors Can Expect Revenue and Profit to Rise FurtherThe Motley Fool X

16 hours Nvidia Stock Investors Can Expect Revenue and Profit to Rise FurtherThe Motley Fool X

16 hours Kura Oncology, Inc. (KURA): Among the Most Promising Cancer Stocks According to Hedge FundsInsider Monkey X

16 hours Moderna Inc. (MRNA): Among the Most Promising Cancer Stocks According to Hedge FundsInsider Monkey X

16 hours Iovance Biotherapeutics, Inc. (IOVA): Among the Most Promising Cancer Stocks According to Hedge FundsInsider Monkey X

16 hours Guardant Health, Inc. (GH): Among the Most Promising Cancer Stocks According to Hedge FundsInsider Monkey X

16 hours Tango Therapeutics Inc. (TNGX): Among the Most Promising Cancer Stocks According to Hedge FundsInsider Monkey X

16 hours So Many Days Lost at the Doctor’s OfficeThe New York Times X

16 hours Immunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge FundsInsider Monkey X

16 hours AstraZeneca (AZN): A Top Pick for Hedge Funds Due to Innovation and Rising DemandInsider Monkey X

17 hours ON Semiconductor (ON) Initiated at Overweight by Wells Fargo with $85 Target, Highlighting Gen-AI and EV Growth OpportunitiesInsider Monkey X

17 hours Arm Holdings (ARM) Set for Growth as Wells Fargo Targets $155 with Overweight RatingInsider Monkey X

17 hours Clean Energy Fuels Corp. (CLNE): Analysts Are Bullish On This Oil and Gas Stock NowInsider Monkey X

17 hours Trump Is Going To Turn Penny Stock EV Maker Lucid (LCID) Into a Donut24/7 Wall St. X

17 hours Super Micro (SMCI) Faces Nasdaq Delisting Risk: Compliance Plan in MotionInsider Monkey X

17 hours Intel (INTC) Replaced by NVIDIA on Dow Jones, Marking Shift in Semiconductor Industry LeadershipInsider Monkey X

17 hours Mark Zuckerberg’s Net Worth Nears $200 Billion24/7 Wall St. X

17 hours Nvidia Earnings Impress Again: Is It Safe for New Investors to Buy Nvidia Stock?The Motley Fool X

17 hours Nvidia Earnings Impress Again: Is It Safe for New Investors to Buy Nvidia Stock?The Motley Fool X